Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer.

18F-FDG-PET/CT MRI PERCIST chemotherapy computer tomography dissociative response immunochemotherapy progression pseudoprogression response

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
30 Sep 2022
Historique:
received: 11 07 2022
revised: 21 09 2022
accepted: 22 09 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 15 10 2022
Statut: epublish

Résumé

Background: In head and neck cancer patients, parameters of metabolic and morphologic response of the tumor to single-cycle induction chemotherapy (IC) with docetaxel, cis- or carboplatin are used to decide the further course of treatment. This study investigated the effect of adding a double immune checkpoint blockade (DICB) of tremelimumab and durvalumab to IC on imaging parameters and their significance with regard to tumor cell remission. Methods: Response variables of 53 patients treated with IC+DICB (ICIT) were compared with those of 104 who received IC alone. Three weeks after one cycle, pathologic and, in some cases, clinical and endoscopic primary tumor responses were evaluated and correlated with a change in 18F-FDG PET and CT/MRI-based maximum-standardized uptake values (SUVmax) before (SUVmaxpre), after treatment (SUVmaxpost) and residually (resSUVmax in % of SUVmaxpre), and in maximum tumor diameter (Dmax) before (Dmaxpre) and after treatment (Dmaxpost) and residually (resD). Results: Reduction of SUVmax and Dmax occurred in both groups; values were SUVmaxpre: 14.4, SUVmaxpost: 6.6, Dmaxpre: 30 mm and Dmaxpost: 23 mm for ICIT versus SUVmaxpre: 16.5, SUVmaxpost: 6.4, Dmaxpre: 21 mm, and Dmaxpost: 16 mm for IC alone (all p < 0.05). ResSUVmax was the best predictor of complete response (IC: AUC: 0.77; ICIT: AUC: 0.76). Metabolic responders with resSUVmax ≤ 40% tended to have a higher rate of CR to ICIT (88%; n = 15/17) than to IC (65%; n = 30/46; p = 0.11). Of the metabolic nonresponders (resSUVmax > 80%), 33% (n = 5/15) achieved a clinical CR to ICIT versus 6% (n = 1/15) to IC (p = 0.01). Conclusions: ICIT and IC quickly induce a response and 18F-FDG PET is the more accurate modality for identifying complete remission. The rate of discrepant response, i.e., pCR with metabolic nonresponse after ICIT was >30%.

Identifiants

pubmed: 36230733
pii: cancers14194811
doi: 10.3390/cancers14194811
pmc: PMC9563870
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
Oral Oncol. 2020 Jan;100:104479
pubmed: 31786390
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1158-1167
pubmed: 31760467
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250
pubmed: 30291373
Eur J Cancer. 2017 Feb;72:144-155
pubmed: 28033526
Clin Nucl Med. 2019 Jul;44(7):535-543
pubmed: 31021918
N Engl J Med. 2015 Apr 23;372(17):1598-607
pubmed: 25901426
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33023982
Clin Nucl Med. 2019 Apr;44(4):e272-e279
pubmed: 30688730
Cancer. 2015 Apr 15;121(8):1214-22
pubmed: 25537381
Cancer. 2018 Jul 15;124(14):2906-2922
pubmed: 29671876
Lancet Oncol. 2007 Sep;8(9):797-805
pubmed: 17693134
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Clin Oncol. 2006 Feb 1;24(4):593-8
pubmed: 16380415
Ann Nucl Med. 2022 Jul;36(7):623-633
pubmed: 35534690
Front Oncol. 2020 Sep 18;10:566297
pubmed: 33072599
Lancet Oncol. 2020 Nov;21(11):1413-1422
pubmed: 32979984
Theranostics. 2020 Jan 1;10(2):925-937
pubmed: 31903160
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
J Clin Oncol. 2018 Nov 1;36(31):3077-3083
pubmed: 30016178
Strahlenther Onkol. 2020 Jun;196(6):522-529
pubmed: 32006068
Eur Arch Otorhinolaryngol. 2020 Jan;277(1):245-254
pubmed: 31583430
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1019-1021
pubmed: 31996974
Blood. 2006 Jan 1;107(1):52-9
pubmed: 16150944
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancers (Basel). 2019 Sep 19;11(9):
pubmed: 31546872
BMC Cancer. 2020 Mar 12;20(1):207
pubmed: 32164651
Lancet Oncol. 2020 Feb;21(2):294-305
pubmed: 31952975
Int J Clin Oncol. 2013 Jun;18(3):402-10
pubmed: 22402886
N Engl J Med. 2022 May 26;386(21):1973-1985
pubmed: 35403841
Cancer Immunol Immunother. 2019 Feb;68(2):297-303
pubmed: 30478475
Ann Surg Oncol. 2011 Sep;18(9):2579-84
pubmed: 21409485
Strahlenther Onkol. 2020 Jun;196(6):515-521
pubmed: 31784802

Auteurs

Michael Beck (M)

Clinic of Nuclear Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Sabine Semrau (S)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Marlen Haderlein (M)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Antoniu-Oreste Gostian (AO)

Department of Otolaryngology-Head & Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Julius Hartwich (J)

Clinic of Nuclear Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Sarina Müller (S)

Department of Otolaryngology-Head & Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Annett Kallies (A)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Carol-Immanuel Geppert (CI)

Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Miriam Schonath (M)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Florian Putz (F)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Udo Gaipl (U)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Benjamin Frey (B)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Marc Saake (M)

Department of Diagnostic Radiology, University Hospital of Erlangen, 91054 Erlangen, Bavaria, Germany.

Heinrich Iro (H)

Department of Otolaryngology-Head & Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Michael Uder (M)

Department of Diagnostic Radiology, University Hospital of Erlangen, 91054 Erlangen, Bavaria, Germany.

Arndt Hartmann (A)

Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Torsten Kuwert (T)

Clinic of Nuclear Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Rainer Fietkau (R)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Markus Eckstein (M)

Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Markus Hecht (M)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.

Classifications MeSH